FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer

The US FDA approved daraxonrasib (Rasonque), a breakthrough treatment for pancreatic cancer that nearly doubles patient survival by targeting the KRAS gene mutation. The drug received expedited approval due to its unprecedented efficacy in a hard-to-treat cancer with high mortality.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.